BCL2 and breast carcinoma: In the therapy of breast cancer, patients receive tamoxifen daily for at least 3 months, and Dixon's group[23],[24] demonstrated that clinical response to tamoxifen is associated with increased apoptosis and decreased proliferation of breast cancer cells by detecting surrogate markers of apoptosis (Bcl-2) and mitosis (Ki-S1).